Table of Contents
<< Previous Issue | Oct 2011 (Vol: 2011, Issue: 10) | Next Issue >> |
- Section: Cartoons
-
Whales
- Section: Licensing
-
Merck & Co. Out-Licenses Gene Therapy Portfolio to Finnish Start-Up FKD Therapies
-
BMS Gains Expanded Territorial Rights to Anti-PD-1 Antibody from Ono Pharmaceutical
-
ViroPharma to Develop Intellect Neurosciences’ OX1 for Friedreich’s Ataxia
-
AstraZeneca’s MedImmune In-Licenses Pfizer’s Tremelimumab
-
Gilead Licenses Boehringer Ingelheim’s NCINI Inhibitors for HIV
-
Pfizer Out-Licenses its Pan-HER Inhibitor Neratinib to Puma Biotechnology
- Section: Mergers & Acquisitions
-
Biotie Agrees to Acquire Newron to Strengthen its Late-Stage CNS Pipeline
-
Santen Pharmaceutical Strengthens its Ophthalmology Portfolio with Novagali Pharma Acquisition
- Section: Research & Development
-
BMS/Ambrx Deal Highlights Big Pharma’s Growing Interest in Protein Drug Engineering
-
Lundbeck Invests US$16 M in Proximagen in Strategic CNS Collaboration
-
Galapagos and Servier Form Multiyear Cancer Therapeutics Partnership